0000000000323723

AUTHOR

Giorgio Rossi

0000-0002-9330-7436

showing 6 related works from this author

Magnetic interface formation at Fe/Cr/Fe(100)

1997

Photoemission magnetic dichroism of Fe and Cr 3p core levels was employed to investigate the magnetic order at the Fe/Cr/Fe(100) interface. For submonolayer and monolayer Fe coverages on Cr(100) the interface system appears magnetically frustrated, with no net magnetization along the parallel (antiparallel) direction of the substrate magnetization. The analysis of the Fe 3p photoemission dichroism allows to conclude that, at these low coverages, Fe is magnetically ordered but along an axis lying at 90° from the substrate Fe(100) magnetization, favoring the interpretation of biquadratic coupling between the ultrathin iron overlayer and the bulk iron substrate, across the Cr interlayer.

MagnetismAnalytical chemistrychemistry.chemical_elementSurfaces and InterfacesDichroismCondensed Matter PhysicsSurfaces Coatings and FilmsOverlayerMagnetizationCrystallographyChromiumTransition metalchemistryX-ray photoelectron spectroscopyMonolayerMaterials Chemistry
researchProduct

Fe 2p photoemission magnetic dichroism with linearly polarized synchrotron radiation and with unpolarized A1 Kα radiation

1997

We report on the measurements and analysis of Fe 2p magnetic dichroism in the angular distribution of the photoelectrons from remanently magnetized Fe(100)surfaces with unpolarized, monochromatized A1 Kα X-rays of 1486 eV energy (MDAD)and with linearly polarized synchrotron radiation of energy 800 eV (LMDAD). The two experiments verify the atomic photoionization model of (L)MDAD including the dichroism effect between field-averaged experiments of different chirality.

Chemistrybusiness.industryLinear polarizationSynchrotron radiationSurfaces and InterfacesPhotoionizationPhotoelectric effectRadiationDichroismCondensed Matter PhysicsSurfaces Coatings and FilmsOpticsX-ray photoelectron spectroscopyMaterials ChemistryAtomic physicsbusinessChirality (chemistry)Surface Science
researchProduct

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial

2016

International audience; BACKGROUND:We investigated whether sirolimus-based immunosuppression improves outcomes in liver transplantation (LTx) candidates with hepatocellular carcinoma (HCC).METHODS:In a prospective-randomized open-label international trial, 525 LTx recipients with HCC initially receiving mammalian target of rapamycin inhibitor-free immunosuppression were randomized 4 to 6 weeks after transplantation into a group on mammalian target of rapamycin inhibitor-free immunosuppression (group A: 264 patients) or a group incorporating sirolimus (group B: 261). The primary endpoint was recurrence-free survival (RFS); intention-to-treat (ITT) analysis was conducted after 8 years. Overal…

MaleTime FactorsIntention to Treat Analysimedicine.medical_treatmentMedizinPROGRESSIONKaplan-Meier EstimateLiver transplantationGastroenterologyImmunosuppressive Agent0302 clinical medicineEVEROLIMUSRENAL-CELL CARCINOMARisk FactorsMedicine and Health SciencesClinical endpointAge FactorSirolimuProspective StudiesIMMUNOSUPPRESSIONTOR Serine-Threonine KinaseTOR Serine-Threonine KinasesHazard ratioLiver NeoplasmsAge FactorsImmunosuppressionMiddle AgedCANCER3. Good healthIntention to Treat AnalysisEuropeRAPAMYCIN INHIBITORSTreatment OutcomeTARGETLocalLiver Neoplasm030220 oncology & carcinogenesisCombinationDisease ProgressionSURVIVAL[SDV.IMM]Life Sciences [q-bio]/Immunology030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleImmunosuppressive Agentsmedicine.drugHumanAdultmedicine.medical_specialtyCanadaCarcinoma HepatocellularTime Factor[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/SurgeryRisk AssessmentDisease-Free Survival03 medical and health sciencesYoung AdultDrug TherapyInternal medicinemedicineHumansAdult; Age Factors; Aged; Australia; Canada; Carcinoma Hepatocellular; Disease Progression; Disease-Free Survival; Drug Therapy Combination; Europe; Female; Humans; Immunosuppressive Agents; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence Local; Prospective Studies; Risk Assessment; Risk Factors; Sirolimus; TOR Serine-Threonine Kinases; Time Factors; Treatment Outcome; Young Adult; Liver Transplantation; TransplantationRECURRENCEMETAANALYSISAgedSirolimusTransplantationEverolimusIntention-to-treat analysisbusiness.industryRisk FactorCarcinomaAustraliaHepatocellular3126 Surgery anesthesiology intensive care radiologySurgeryLiver TransplantationTransplantationProspective StudieNeoplasm RecurrenceSirolimusNeoplasm Recurrence Localbusiness
researchProduct

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing live…

2010

Abstract Background The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure oncology setting, and at present, no oncology endpoint-directed RCT has been reported in the high-malignancy risk population of immunosuppressed transplant recipients. Interestingly, since mTOR inhibitors have both immunosuppressive and anti-cancer effects, they have the potential to simultaneously protect against immunologic graft loss and tumour development. Therefore, we designed a prospective RCT to determine if the mTOR inhibito…

OncologyCancer ResearchTime Factorsmedicine.medical_treatmentMedizinIntracellular Signaling Peptides and Proteins - antagonists & inhibitors metabolismKaplan-Meier Estimate312 Clinical medicineProtein-Serine-Threonine KinaseLiver transplantationTHERAPYStudy ProtocolImmunosuppressive Agentendothelial growth-factor renal-cell carcinoma tumor progression rapamycin cancer cyclosporine efficacy therapy target model0302 clinical medicineRENAL-CELL CARCINOMARisk FactorsRecurrenceSurgical oncologyMedicine and Health SciencesLiver Neoplasms - drug therapy enzymology mortality surgerySirolimuProspective StudiesTUMOR PROGRESSIONTransplantation Homologoueducation.field_of_studyliver transplantationTOR Serine-Threonine KinasesLiver NeoplasmsIntracellular Signaling Peptides and ProteinsImmunosuppressionhepatocellular carcinomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCANCER3. Good healthEuropeMulticenter StudyTreatment OutcomeTARGETsirolimusOncologyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaRandomized Controlled TrialmTORCarcinoma Hepatocellular - drug therapy enzymology mortality surgery030211 gastroenterology & hepatologyImmunosuppressive AgentsRCTHumanmedicine.drugCanadamedicine.medical_specialtyCarcinoma HepatocellularTime FactoreducationPopulationLiver Transplantation - adverse effects mortalityProtein Serine-Threonine Kinaseslcsh:RC254-282Disease-Free Survival03 medical and health sciencesInternal medicineGeneticsmedicineTransplantation HomologousHumansComparative StudyRapamycinddc:610educationProtein-Serine-Threonine Kinases - antagonists & inhibitors metabolismKaplan-Meiers Estimatebusiness.industryRisk FactorAustraliaImmunosuppressive Agents - therapeutic useSirolimus - therapeutic useEFFICACYHumans; Liver Transplantation; Hepatocellular Carcinoma; Randomized Controlled Trial; RCT; Multicenter Study; Comparative Study; Rapamycin; mTOR; Sirolimusmedicine.diseaseSurgeryMODELTransplantationClinical trialProspective StudieIntracellular Signaling Peptides and ProteinSirolimusENDOTHELIAL GROWTH-FACTORCYCLOSPORINERAPAMYCINbusiness
researchProduct

Interobserver Agreement in the Diagnosis of Multiple Sclerosis

1989

• Interobserver agreement in the clinical diagnosis of multiple sclerosis (MS) among six neurologists was evaluated. Three of them participated in a study of the clinical diagnosis of MS, the Italian Multicenter Study (IMS). The raters examined the clinical forms of MS of 50 patients randomly selected from among 430 patients recruited from the IMS. For each patient, neurologists were asked to make a diagnosis according to the McDonald-Halliday classification system of MS. The overall agreement on the diagnosis (MS present or absent) was fair, with no difference noted between the two groups of raters. Considering the six diagnostic levels instead, the reliability was higher for the neurologi…

AdultMalePediatricsmedicine.medical_specialtyMultiple Sclerosisbusiness.industryMultiple sclerosisMethodDiseasemedicine.diseaseSurgeryClinical trialArts and Humanities (miscellaneous)Multicenter studyClinical diagnosisMultiple SclerosiMethodsmedicineHumansFemaleNeurology (clinical)businessReliability (statistics)HumanArchives of Neurology
researchProduct

Psychopathology, Dissociation and Somatic Symptoms in Adolescents Who Were Exposed to Traumatic Experiences

2018

Background: The direct and long-term effects of children’s exposure to traumatic events can be seen in a complex continuum, based first of all on the type of trauma. Children’s reactions to trauma may have different manifestations from the clinical picture of the PTSD, exhibiting dissociative, somatic, depressive or anxiety symptoms, and/or disruptiveness. Aim: we conducted a cross-sectional study in a psychiatric patients sample to determine the extent to which complex trauma history is associated with disease-related characteristics (diagnosis, dissociative symptoms, somatic symptomatology, impairment degree). Methods: We have enrolled 107 subjects, aged between 12 and 18 years, who conse…

Psychology (all)medicine.drug_classmedia_common.quotation_subjectlcsh:BF1-990CBCLdissociationDissociative03 medical and health sciences0302 clinical medicinePsychoticismmedicinePsychologyPersonalitysomatic symptomsadolescentsGeneral PsychologyAdolescents; Complex trauma; Dissociation; PTSD; Somatic symptoms; Psychology (all)Original Researchmedia_commonPTSDmedicine.diseaseComorbidity030227 psychiatrycomplex traumaMoodlcsh:PsychologyAnxietymedicine.symptomPsychology030217 neurology & neurosurgeryPsychopathologyClinical psychologyFrontiers in Psychology
researchProduct